Pharmaceutical Technology

MAY 12, 2023

BioNTech has ended its research collaboration with Matinas after its oral mRNA vaccine failed to demonstrate preclinical activity. Whilst the formulation had been successful in vitro , the oral administration in mice did not elicit activity. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccination 130

Vaccination Vaccine In-Vivo In-Vitro 130

Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Companies Offering Bioassay Services for Cell and Gene Therapies. How Players are Complying with Developing Market?

Bioassay 52

Bioassay Gene Therapy Gene Development 52

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 73

Research Gene Therapy In-Vivo In-Vitro 73

Scienmag

DECEMBER 10, 2020

Credit: Nucleic Acids Research Scientists at Tokyo Institute of Technology decipher how to quantitatively assess the effects of specific epigenetic changes on the rate of transcription by developing a mathematical model. For this, they successfully generated reconstituted chromatin bearing histone modifications in vitro.

Gene Expression 52

Gene Expression In-Vitro Gene Scientist 52

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

Drug Discovery World

MAY 1, 2023

Download Emulate’s Introduction to Organ-on-a-Chip Technology eBook to learn about: What Organ-Chips are, how they work, and why they are transforming the way drugs are discovered and developed How Organ-Chips overcome the main challenges of conventional in vivo and in vitro models The wide variety of insights and endpoint analyses Organ-on-a-Chip (..)

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Etienne De Braekeleer, Senior Research Scientist, AstraZeneca.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Drug Discovery World

MAY 1, 2023

The post New eBook: An introduction to organ-on-a-chip technology appeared first on Drug Discovery World (DDW).

In-Vivo 52

In-Vivo In-Vitro Gene Therapy Gene 52

XTalks

APRIL 13, 2021

Now, thanks to a study funded by the National Institutes of Health Intramural Research Program, scientists have discovered that ?-synuclein, The researchers presented their results at the spring meeting of the American Chemical Society (ACS), which is being held online April 5 to 30. Additionally, higher levels of ?-synuclein

Research 98

Research Protein In-Vitro Gene Therapy 98

Drug Discovery World

DECEMBER 13, 2022

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene. One form of FCMD is caused by a genetic abnormality in the ‘fukutin’ (FKTN) gene.

RNA 52

RNA Genetics Gene In-Vitro 52

XTalks

SEPTEMBER 30, 2020

While it remains unclear why some people become more gravely ill than others when infected with the SARS-CoV-2 virus that causes COVID-19, researchers have found that an immune deficiency may be part of it. Two recent studies have shown that individuals who lack an important immune factor may have reduced ability to fight the virus.

Antibody 135

Antibody Genetics Research In-Vitro 135

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process. This article is sponsored by Charles River.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

JANUARY 17, 2024

Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. The research team conducted experiments involving ‘Mitofusin2’ (MFN2), a protein that is necessary for mitochondria tethering in MAMs. The results were consistent with the in vitro experiments.

In-Vitro 52

In-Vitro Regulation Protein Gene 52

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were there to present the latest findings from our research. MT: What’s next for STORM’s research? MT: What data did you present at the conference?

RNA 65

RNA In-Vivo In-Vitro DNA 65

Drug Discovery World

AUGUST 22, 2023

In addition, total blood levels of sulforaphane (SFN) and SFN-metabolites were confirmed in the micromolar range, where efficacy is seen in vitro. Evgen Pharma has revealed the final data from its Phase Ib healthy volunteer study using the company’s new enteric coated tablet formation of its lead asset SFX-01.

Gene Expression 52

Gene Expression In-Vitro Gene Trials 52

Drug Discovery World

FEBRUARY 6, 2024

Target identification and validation are where there is huge impact; simply put, genomics can be used to identify new drug targets by identifying genes that are overexpressed or mutated in diseased tissues. She speaks to Megan Thomas on how genomics can advance drug discovery and development.

Genome 59

Genome Genomics Genetics In-Vitro 59

pharmaphorum

FEBRUARY 19, 2021

Snipping out this viral code with powerful CRISPR gene editing technology, which last year won Drs Emmanuelle Charpentier and Jennifer Doudna the Nobel Prize for chemistry, would in theory prevent the need for drugs to suppress the virus and the development of AIDS. The post Could CRISPR cure HIV?

Gene Editing 106

Gene Editing In-Vivo DNA In-Vitro 106

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

FDA Law Blog

MARCH 31, 2024

Committee Chair Rodgers expressed her concerns that FDA regulation of LDTs would substantially increase the regulatory and financial burden on labs, causing them to stop offering many tests, such as those that are used in oncology and cell and gene therapies. This seems to have been the outcome that many lawmakers desired.

Regulation 64

Regulation In-Vitro Development Gene Therapy 64

Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. Optimer binders are engineered to overcome these problems.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

JULY 10, 2023

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. In response, researchers often breed several founders. Host embryos from a different inbred strain are traditionally used.

Genetics 52

Genetics Gene Editing Genetic Engineering In-Vitro 52

XTalks

APRIL 6, 2022

Lung cancer is the most common cancer in men and the third most common cancer in women, according to global lung cancer statistics by the World Cancer Research Fund. The researchers observed lead times of approximately 200 days from the detection of ctDNA to cancer recurrence. Photo source: Inivata.

DNA 105

DNA In-Vitro Doctors Doctor 105

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

STAT News

FEBRUARY 23, 2023

Researchers are now exploring whether to offer the surgery more widely. The  Ovarian Cancer Research Alliance , a leading ovarian cancer research organization, released new guidance Jan. Research suggests that salpingectomies can significantly lower, if not eliminate, the risk of ovarian cancer.

Genetics 111

Genetics In-Vitro Research Gene 111

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

NOVEMBER 16, 2022

DDW Editor Reece Armstrong learns about Molecular Devices’ Organoid Innovation Centre (OIC) and how the company is aiming to advance research into 3D biology and organoids. . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

DECEMBER 20, 2020

Athenex and Almirall have a license deal with Almirall having the license to research, develop and commercialize the drug in the U.S. The data supported the potential benefits of the drug for OAB in patients with urge urinary incontinence (UUI), urgency, and urinary frequency. The drug is a once-daily, beta-3 adrenergic agonist.

In-Vitro 52

In-Vitro FDA Approval Manufacturing Licensing 52

The Pharma Data

MAY 31, 2022

Of the babies with 2 or 3 copies of the SMN2 gene (n=6), 100% were able to sit after one year of treatment with Evrysdi, 67% could stand and 50% of infants could walk independently. . Jude Children’s Research Hospital. Evrysdi is now approved in the US to treat SMA in children and adults of all ages.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

Delveinsight

JANUARY 12, 2021

The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model. Bluebird spins off to two companies, cleaving off its gene therapy, and cancer units. Further, Birinapant also complements the anti-tumor activity of the immune system.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Drug Discovery World

AUGUST 3, 2022

Bachem has spent time studying and researching this reaction, along with the side-reactions that happen during the coupling stage. Plus, in numerous in vitro experiments, the conjugate has been able to specifically enter ? However, this method does come with one major drawback. The table below includes some of these examples.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Drug Discovery World

FEBRUARY 9, 2024

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. Chris explained that DefiniGEN is a liver cell company focussed on hepatocytes, particularly supporting the drug development industry in producing liver therapies.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

SEPTEMBER 19, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Gene Therapy 52

Gene Therapy Gene Development Protein 52

pharmaphorum

MARCH 15, 2022

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. The post Illumina debuts its multi-gene test for cancer in Europe appeared first on.

Gene 52

Gene Genome Genomics Gene Sequencing 52

Drug Discovery World

SEPTEMBER 12, 2023

Primary hepatocytes represent the gold standard in vitro cell model for functionality, however, when isolated from liver tissue, primary cells maintain expression of key proteins for only a short period. However, hepatoma lines may lack the key proteins essential for modeling.

Gene Therapy 52

Gene Therapy Gene Development Drugs 52